Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RN7SK pseudogene 22 (RN7SKP22) is a processed pseudogene related to RN7SK, a small nuclear non-coding RNA involved in the regulation of transcription elongation by controlling the activity of positive transcription elongation factor b (P-TEFb)[3][1][2]. As a pseudogene, RN7SKP22 is generally believed to be non-functional and does not encode a protein or a functional RNA product. Its precise biological roles, if any, are not established, and it is not considered a therapeutic target. The functional importance described in the literature pertains to the parent gene RN7SK, not RN7SKP22. There is no evidence of RN7SKP22 acting as a receptor, enzyme, or being directly linked to any disease or therapeutic interventions[4][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RN7SK pseudogene 22 (RN7SKP22).